Rating Rationale
September 27, 2021 | Mumbai
Mahatma Gandhi University of Medical Sciences and Technology
Ratings upgraded to 'CRISIL A-/Stable/CRISIL A2+'; rated amount enhanced for Bank Debt
 
Rating Action
Total Bank Loan Facilities RatedRs.510 Crore (Enhanced from Rs.458 Crore)
Long Term RatingCRISIL A-/Stable (Upgraded from 'CRISIL BBB+/Stable')
Short Term RatingCRISIL A2+ (Upgraded from 'CRISIL A2')
1 crore = 10 million
Refer to Annexure for Details of Instruments & Bank Facilities

Detailed Rationale

CRISIL Ratings has upgraded its ratings on the bank facilities of Mahatma Gandhi University of Medical Sciences and Technology (MGUMST) to ‘CRISIL A-/Stable/CRISIL A2+’ from ‘CRISIL BBB+/Stable/CRISIL A2’.

 

The upgrade reflects the improvement in the business risk profile of MGUMST driven by timely completion of capacity expansion and improved occupancy in the hospital and medical college, which should lead to higher revenue over the medium term. The financial risk profile and liquidity will benefit from better operating surplus leading to higher debt service coverage ratio (DSCR).

 

The performance was impacted in the first half of fiscal 2021 and revenue declined around 37% on-year. However, the university took quick corrective steps to speed up collections and a significant portion of beds were allocated for Covid care, which compensated for loss of revenue from the non-Covid segment, resulting in revenue growth of around 2% on-year for the hospital for fiscal 2021. Admissions for MBBS and other undergraduate courses were delayed to around January 2021. No material decline in occupancy and subsequent timely collection of admission fees resulted in revenue growth of 10.3% on-year for the medical college. The growth was also supported by addition of 96 seats, despite lower hostel income and some non-clinical seats in PG remaining unoccupied due to the pandemic.

 

From fiscal 2022, addition of 100 seats in the MBBS course, 40 seats in the BDS course and the second batch for postgraduate courses will increase the overall student capacity by 224. There are several batches with lower fees, which will graduate in the current year. The batches thereafter have higher fees per annum which will lead to increase in average fee per student per annum. Increased capacity and higher average fee per student, along with track record of healthy occupancy, should support revenue growth in the education division in fiscal 2022 and thereafter. The hospital is also expected to see increase in revenue because of addition of around 210 beds and supported by the speciality division which houses high-revenue procedures such as oncology which has pent-up demand in the region. Beds were added in fiscal 2021 and fiscal 2022 will be the first full year of operations.

 

The second wave of Covid-19 during the first quarter of fiscal 2022 has not affected revenue or profitability as was earlier expected. MGUMST recorded revenue of Rs 127.65 crore and operating surplus of around Rs 36.25 crore (28.4%) and cash accrual of around Rs 28.29 crore for the period.

Operating surplus was healthy at 24-26% in the three years through fiscal 2021 and is expected to improve, backed by addition of students and hospital beds with no large additional operating expense.

 

Higher revenue and operating surplus will increase the cash generating ability going forward. The financial risk profile has improved due to higher revenue and the expected improvement in profitability should lead to a better DSCR.

 

Liquidity improved backed by unencumbered liquid funds of around Rs 34.6 crore and cushion in bank lines of Rs 3.64 crore as on June 30, 2021. The liquidity cushion (cash and bank balance and unutilised bank lines) averaged Rs 56 crore in fiscal 2021 and is expected to improve with no major debt funded capex plan over the next 2-3 years.

 

The ratings continue to reflect the university’s sound track record in medical education and hospital management, strong operating efficiency and healthy occupancy ratio. The ratings also factor in support from the trustees and the management’s healthy reputation along with the university’s large and increasing scale of operations and profitability. These strengths are partially offset by regulatory risks amid the pandemic and the likely competition from upcoming government medical colleges.

Key Rating Drivers & Detailed Description

Strengths:

* Sound track record: MGUMST, earlier managed by the Indian Education Trust (IET) , started operations with a hospital in 2001 and later set up a medical college. In 2011, it was granted the university status under the Jaipur Ordinance, 2011 (Ordinance number 4), by the Governor of Rajasthan. Over the years, the university has expanded its reach and range of offerings and built a strong reputation.

 

* Healthy occupancy of college seats: The university reported 100% occupancy across all departments over the three academic years through 2020. In academic year 2021, occupancy declined to around 96% on account of Covid-19. With the college’s track record and strong reputation, occupancy is likely to return to 100% in academic year 2022 as the pandemic situation improves.

 

* Strong operating efficiency: Healthy occupancy for medical courses as well as the hospital resulted in operating margin of 25.7% in fiscal 2020 (up from 24.09% in fiscal 2019), translating into moderate return on capital employed (RoCE) of above 15% in fiscal 2020. Operating margin and RoCE were earlier expected to decline in fiscal 2021. However, timely admissions and improvement in occupancy at the hospital helped sustain the operating margin at 24.7% or the fiscal.

 

* Support from the trustees and healthy reputation of the management: The trustees have provided consistent support in shaping the quality of education provided at the university. Apart from overseeing operations at the university, they have implemented best practices from their decade-long experience in the education and hospital management sectors. They also provided unsecured loans during the university’s expansion phase.

 

* Large scale of operations and healthy profitability: Revenue is estimated at Rs 385 crore in fiscal 2021 vis-à-vis Rs 358.93 crore in fiscal 2020, and has increased considerably from Rs 161.3 crore in fiscal 2016. With commencement of the Doctor of Medicine (MD), Master of Surgery (MS) and Doctorate of Medicine (DM) courses in fiscal 2021; increase in hospital beds to 210; addition of 100 seats in the MBBS course; and radiation blocks and other labs likely in fiscals 2022 and 2023, receipts may increase. Hospital receipts have not grown significantly because of the fall in occupancy in the non-Covid-19 division in the first half of fiscal 2021. Gradual recovery is expected over the medium term, along with traction in new courses.

 

Weaknesses:

* Susceptibility to regulatory changes: Establishment and operations of educational institutions are regulated by various governmental and quasi-governmental agencies, such as the University Grants Commission, All India Council for Technical Education, universities, state governments, Medical Council of India and Indian Nursing Council. Each body has detailed procedures for granting permission to set up institutions, and approvals need to be renewed every three or five years. Also, the university needs to regularly invest in its workforce and infrastructure. Any non-compliance would result in cancellation of affiliation and license, leading to loss of reputation for the college and revenue for the trust.

 

Also, regulatory changes - such as changes in the student-teacher ratio, increase in minimum infrastructure, and control over fees - could have a disruptive effect on some private educational institutions. In fiscal 2021, the hospital offered around 700 hospital beds for Covid-19 patients. However, the charges are decided by the state government. Furthermore, the state government has mandated services to be provided within the stipulated tariff. Hence, MGUMST has limited control over charges for its premium services.

 

* Likely competition from upcoming government medical colleges: While government colleges have high demand because of their low fees, the demand-supply mismatch has augured well for private colleges. However, the government has begun to acknowledge the steep gap between demand for medical colleges and their availability and has started to act upon it. Government actions include relaxation of norms for private colleges and universities, along with addition of government colleges. In 2019, the government gave the nod for setting up 75 medical colleges. Previously, the government had extended permission for 58 medical colleges in phase I and 24 in phase II. This led to addition of 15,700 MBBS seats across the country. Furthermore, in academic year 2019-20, government colleges saw the highest addition of MBBS seats, at 2,750 in 25 new government colleges. Therefore, addition of government colleges with substantially lower fees could lure students away from private colleges.

Liquidity: Strong

Liquidity is expected to remain healthy. Cash accrual (estimated at Rs 67.12 crore in fiscal 2021), expected at Rs 100 crore, Rs 140 crore and Rs 170 crore in fiscals 2022, 2023 and 2024, respectively, will sufficiently cover yearly maturing debt of Rs 33-40 crore. Improvement in cash accrual is aided by recovery of the hospital division and courses added in the past two years.

 

The debt repayment is structured such that the major debt obligation for the year is due in October after receipt of fees in the education department. However, admissions to the MBBS course were delayed in fiscal 2021, as entrance examinations were not held on time, narrowing the liquidity cushion. DSCR should remain comfortable at a minimum of 1.96 times over the medium term. Utilisation of bank overdraft averaged 45% over the 12 months through July 2021

Outlook: Stable

MGUMST will maintain its financial risk profile and sustain its operating income over the medium term, supported by its strong reputation and brand.

Rating Sensitivity Factors

Upward factors

  • Ramp-up of the newly added hospital division and expansion of capacity in the college leading to DSCR above 2.3 times
  • Efficient working capital management resulting in higher profitability and build-up of liquid funds
  • Prepayment of term loans improving the financial risk profile, particularly debt protection metrics

 

Downward factors

  • Regulatory changes impacting the performance of the university
  • Fall in DSCR to below 1.7 times
  • Substantial delay in receipt of tuition or admission fees leading to a short-term liquidity crunch
  • Major debt funded capex impacting financial risk profile and debt protection metrics.

About the University

MGUMST is a Jaipur-based private university and one of the largest private hospitals in Rajasthan, spread across 36 acres. It gained university status in 2011. The university offers medical, nursing and dental courses and provides inpatient and outpatient healthcare services through 1,472 beds under Mahatma Gandhi Hospital. IET is the sponsoring body of MGUMST. Dr M L Swarankar, Ms Meena Swarankar, Mr R Soni and Ms Neelam Soni are the founder-promoters of IET.

Key Financial Indicators

Particulars

Unit

2021*

2020

Revenue

Rs.Crore

385

358.93

Profit After Tax (PAT)

Rs.Crore

54.82

43.30

PAT Margin

%

14.24

12.09

Adjusted debt/adjusted networth

Times

1.41

1.62

Interest coverage

Times

3.37

3.22

*Provisional

Any other information: Not applicable

Note on complexity levels of the rated instrument:
CRISIL Ratings' complexity levels are assigned to various types of financial instruments. The CRISIL Ratings' complexity levels are available on www.crisil.com/complexity-levels. Users are advised to refer to the CRISIL Ratings' complexity levels for instruments that they consider for investment. Users may also call the Customer Service Helpdesk with queries on specific instruments.

Annexure - Details of Instrument(s)

ISIN

Name of instrument

Date of allotment

Coupon rate (%)

Maturity date

Issue size (Rs.Crore)

Complexity level

Rating assigned with outlook

NA

Bank guarantee

NA

NA

NA

24.2

NA

CRISIL A2+

NA

Long-term loan

NA

NA

Dec-33

449.13

NA

CRISIL A-/Stable

NA

Overdraft facility

NA

NA

NA

35.97

NA

CRISIL A-/Stable

NA

Proposed long-term bank loan facility

NA

NA

NA

0.7

NA

CRISIL A-/Stable

Annexure - Rating History for last 3 Years
  Current 2021 (History) 2020  2019  2018  Start of 2018
Instrument Type Outstanding Amount Rating Date Rating Date Rating Date Rating Date Rating Rating
Fund Based Facilities LT 485.8 CRISIL A-/Stable 02-06-21 CRISIL BBB+/Stable 14-10-20 CRISIL BBB+/Watch Developing   --   -- --
      -- 12-01-21 CRISIL BBB+/Watch Developing 07-01-20 CRISIL BBB+/Stable   --   -- --
Non-Fund Based Facilities ST 24.2 CRISIL A2+ 02-06-21 CRISIL A2 14-10-20 CRISIL A2/Watch Developing   --   -- --
      -- 12-01-21 CRISIL A2/Watch Developing 07-01-20 CRISIL A2   --   -- --
All amounts are in Rs.Cr.
 
Annexure - Details of Bank Lenders & Facilities
Facility Amount (Rs.Crore) Name of Lender Rating
Bank Guarantee 0.65 IDBI Bank Limited CRISIL A2+
Bank Guarantee 8.5 Canara Bank CRISIL A2+
Bank Guarantee 4 Punjab National Bank CRISIL A2+
Bank Guarantee 11.05 Punjab National Bank CRISIL A2+
Long Term Loan 1.94 IDBI Bank Limited CRISIL A-/Stable
Long Term Loan 73.67 Canara Bank CRISIL A-/Stable
Long Term Loan 78.2 Punjab National Bank CRISIL A-/Stable
Long Term Loan 160.8 Punjab National Bank CRISIL A-/Stable
Long Term Loan 0.11 Indian Bank CRISIL A-/Stable
Long Term Loan 83.11 Union Bank of India CRISIL A-/Stable
Long Term Loan 28.29 Punjab National Bank CRISIL A-/Stable
Long Term Loan 2.42 Indian Bank CRISIL A-/Stable
Long Term Loan 11.6 Union Bank of India CRISIL A-/Stable
Long Term Loan 8.99 Canara Bank CRISIL A-/Stable
Overdraft Facility 12.2 Indian Bank CRISIL A-/Stable
Overdraft Facility 23.77 Punjab National Bank CRISIL A-/Stable
Proposed Long Term Bank Loan Facility 0.7 Not Applicable CRISIL A-/Stable
This Annexure has been updated on 27-Sep-2021 in line with the lender-wise facility details as on 27-Sep-2021 received from the rated entity
Criteria Details
Links to related criteria
CRISILs Approach to Financial Ratios
Rating criteria for manufaturing and service sector companies
CRISILs Bank Loan Ratings - process, scale and default recognition
CRISILs criteria for rating Education institutions
CRISILs Criteria for rating short term debt

Media Relations
Analytical Contacts
Customer Service Helpdesk
Saman Khan
Media Relations
CRISIL Limited
D: +91 22 3342 3895
B: +91 22 3342 3000
saman.khan@crisil.com

Naireen Ahmed
Media Relations
CRISIL Limited
D: +91 22 3342 1818
B: +91 22 3342 3000
 naireen.ahmed@crisil.com

Jaya Mirpuri
Director
CRISIL Ratings Limited
D:+91 22 4040 5805
jaya.mirpuri@crisil.com


Argha Chanda
Associate Director
CRISIL Ratings Limited
D:+91 33 4011 8210
Argha.Chanda@crisil.com


Amlan Ray
Manager
CRISIL Ratings Limited
B:+91 33 4011 8200
Amlan.Ray@crisil.com
Timings: 10.00 am to 7.00 pm
Toll free Number:1800 267 1301

For a copy of Rationales / Rating Reports:
CRISILratingdesk@crisil.com
 
For Analytical queries:
ratingsinvestordesk@crisil.com


 

Note for Media:
This rating rationale is transmitted to you for the sole purpose of dissemination through your newspaper / magazine / agency. The rating rationale may be used by you in full or in part without changing the meaning or context thereof but with due credit to CRISIL Ratings. However, CRISIL Ratings alone has the sole right of distribution (whether directly or indirectly) of its rationales for consideration or otherwise through any media including websites, portals etc.


About CRISIL Ratings Limited (A subsidiary of CRISIL Limited)

CRISIL Ratings pioneered the concept of credit rating in India in 1987. With a tradition of independence, analytical rigour and innovation, we set the standards in the credit rating business. We rate the entire range of debt instruments, such as, bank loans, certificates of deposit, commercial paper, non-convertible / convertible / partially convertible bonds and debentures, perpetual bonds, bank hybrid capital instruments, asset-backed and mortgage-backed securities, partial guarantees and other structured debt instruments. We have rated over 33,000 large and mid-scale corporates and financial institutions. We have also instituted several innovations in India in the rating business, including rating municipal bonds, partially guaranteed instruments and infrastructure investment trusts (InvITs).
 
CRISIL Ratings Limited ("CRISIL Ratings") is a wholly-owned subsidiary of CRISIL Limited ("CRISIL"). CRISIL Ratings Limited is registered in India as a credit rating agency with the Securities and Exchange Board of India ("SEBI").
 
For more information, visit www.crisilratings.com 




About CRISIL Limited

CRISIL is a global analytical company providing ratings, research, and risk and policy advisory services. We are India's leading ratings agency. We are also the foremost provider of high-end research to the world's largest banks and leading corporations.

CRISIL is majority owned by S&P Global Inc., a leading provider of transparent and independent ratings, benchmarks, analytics and data to the capital and commodity markets worldwide


For more information, visit www.crisil.com

Connect with us: TWITTER | LINKEDIN | YOUTUBE | FACEBOOK


CRISIL PRIVACY NOTICE
 
CRISIL respects your privacy. We may use your contact information, such as your name, address, and email id to fulfil your request and service your account and to provide you with additional information from CRISIL.For further information on CRISIL’s privacy policy please visit www.crisil.com.


DISCLAIMER

This disclaimer forms part of and applies to each credit rating report and/or credit rating rationale (each a "Report") that is provided by CRISIL Ratings Limited  (hereinafter referred to as "CRISIL Ratings") . For the avoidance of doubt, the term "Report" includes the information, ratings and other content forming part of the Report. The Report is intended for the jurisdiction of India only. This Report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the Report is to be construed as CRISIL Ratings providing or intending to provide any services in jurisdictions where CRISIL Ratings does not have the necessary licenses and/or registration to carry out its business activities referred to above. Access or use of this Report does not create a client relationship between CRISIL Ratings and the user.

We are not aware that any user intends to rely on the Report or of the manner in which a user intends to use the Report. In preparing our Report we have not taken into consideration the objectives or particular needs of any particular user. It is made abundantly clear that the Report is not intended to and does not constitute an investment advice. The Report is not an offer to sell or an offer to purchase or subscribe for any investment in any securities, instruments, facilities or solicitation of any kind or otherwise enter into any deal or transaction with the entity to which the Report pertains. The Report should not be the sole or primary basis for any investment decision within the meaning of any law or regulation (including the laws and regulations applicable in the US).

Ratings from CRISIL Ratings are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold, or sell any securities / instruments or to make any investment decisions. Any opinions expressed here are in good faith, are subject to change without notice, and are only current as of the stated date of their issue. CRISIL Ratings assumes no obligation to update its opinions following publication in any form or format although CRISIL Ratings may disseminate its opinions and analysis. Rating by CRISIL Ratings contained in the Report is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment or other business decisions. The recipients of the Report should rely on their own judgment and take their own professional advice before acting on the Report in any way. CRISIL Ratings or its associates may have other commercial transactions with the company/entity.

Neither CRISIL Ratings nor its affiliates, third party providers, as well as their directors, officers, shareholders, employees or agents (collectively, "CRISIL Ratings Parties") guarantee the accuracy, completeness or adequacy of the Report, and no CRISIL Ratings Party shall have any liability for any errors, omissions, or interruptions therein, regardless of the cause, or for the results obtained from the use of any part of the Report. EACH CRISIL RATINGS' PARTY DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY, SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall any CRISIL Ratings Party be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the Report even if advised of the possibility of such damages.

CRISIL Ratings may receive compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors. CRISIL Rating's public ratings and analysis as are required to be disclosed under the regulations of the Securities and Exchange Board of India (and other applicable regulations, if any) are made available on its web sites, www.crisil.com (free of charge). Reports with more detail and additional information may be available for subscription at a fee - more details about ratings by CRISIL Ratings are available here: www.crisilratings.com.

CRISIL Ratings and its affiliates do not act as a fiduciary. While CRISIL Ratings has obtained information from sources it believes to be reliable, CRISIL Ratings does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives and / or relies in its Reports. CRISIL Ratings has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process. CRISIL Ratings has in place a ratings code of conduct and policies for analytical firewalls and for managing conflict of interest. For details please refer to: http://www.crisil.com/ratings/highlightedpolicy.html

Rating criteria by CRISIL Ratings are generally available without charge to the public on the CRISIL Ratings public web site, www.crisil.com. For latest rating information on any instrument of any company rated by CRISIL Ratings you may contact CRISIL RATING DESK at CRISILratingdesk@crisil.com, or at (0091) 1800 267 1301.

This Report should not be reproduced or redistributed to any other person or in any form without a prior written consent of CRISIL Ratings.

All rights reserved @ CRISIL Ratings Limited. CRISIL Ratings Limited is a wholly owned subsidiary of CRISIL Limited.

CRISIL Ratings uses the prefix ‘PP-MLD’ for the ratings of principal-protected market-linked debentures (PPMLD) with effect from November 1, 2011 to comply with the SEBI circular, "Guidelines for Issue and Listing of Structured Products/Market Linked Debentures". The revision in rating symbols for PPMLDs should not be construed as a change in the rating of the subject instrument. For details on CRISIL Ratiings' use of 'PP-MLD' please refer to the notes to Rating scale for Debt Instruments and Structured Finance Instruments at the following link: www.crisil.com/ratings/credit-rating-scale.html